References
- Sharma O, Sultan AA, Ding H, Triggle CR. A review of the progress and challenges of developing a vaccine for COVID-19. Front Immunol 2020;11:585354.
- Santi T, Sungono V, Kamarga L, et al. Heterologous prime-boost with the mRNA-1273 vaccine among CoronaVac-vaccinated healthcare workers in Indonesia. Clin Exp Vaccine Res 2022;11:209-16. https://doi.org/10.7774/cevr.2022.11.2.209
- Zhang Y, Zeng G, Pan H, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis 2021;21:181-92. https://doi.org/10.1016/S1473-3099(20)30843-4
- Palacios R, Patino EG, de Oliveira Piorelli R, et al. Double-blind, randomized, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of treating healthcare professionals with the adsorbed COVID-19 (inactivated) vaccine manufactured by Sinovac-PROFISCOV: a structured summary of a study protocol for a randomized controlled trial. Trials 2020;21:853.
- Earle KA, Ambrosino DM, Fiore-Gartland A, et al. Evidence for antibody as a protective correlate for COVID-19 vaccines. Vaccine 2021;39:4423-8. https://doi.org/10.1016/j.vaccine.2021.05.063
- Fu D, Zhang G, Wang Y, et al. Structural basis for SARS-CoV-2 neutralizing antibodies with novel binding epitopes. PLoS Biol 2021;19:e3001209.
- Barnes CO, Jette CA, Abernathy ME, et al. SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies. Nature 2020;588:682-7. https://doi.org/10.1038/s41586-020-2852-1
- World Health Organization. Coronavirus (COVID-19) dashboard [Internet]. Geneva: World Health Organization; 2022 [cited 2022 Sep 9]. Available from: https://covid19.who.int
- Higgins V, Fabros A, Kulasingam V. Quantitative measurement of anti-SARS-CoV-2 antibodies: analytical and clinical evaluation. J Clin Microbiol 2021;59:e03149-20.
- Feng S, Phillips DJ, White T, et al. Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection. Nat Med 2021;27:2032-40. https://doi.org/10.1038/s41591-021-01540-1
- Chakraborty S, Mallajosyula V, Tato CM, Tan GS, Wang TT. SARS-CoV-2 vaccines in advanced clinical trials: where do we stand? Adv Drug Deliv Rev 2021;172:314-38. https://doi.org/10.1016/j.addr.2021.01.014
- Santi T, Samakto B, Kamarga L, Hidayat FK, Hidayat F. Factors associated with SARS-CoV-2 antibody titer after sinovac vaccination among health care workers. Acta Med Indones 2021;53:374-84.
- Angkasekwinai N, Sewatanon J, Niyomnaitham S, et al. Comparison of safety and immunogenicity of CoronaVac and ChAdOx1 against the SARS-CoV-2 circulating variants of concern (Alpha, Delta, Beta) in Thai healthcare workers. Vaccine X 2022;10:100153.
- Foddis R, Marino R, Silvestri R, et al. Evaluation of the anti-spike (RDB) IgG titer among workers employed at the university of pisa vaccinated with different types of SARS-CoV-2 vaccines. Vaccines (Basel) 2022;10:1244.
- Salvagno GL, Henry BM, di Piazza G, et al. Anti-SARS-CoV-2 receptor-binding domain total antibodies response in seropositive and seronegative healthcare workers undergoing COVID-19 mRNA BNT162b2 vaccination. Diagnostics (Basel) 2021;11:832.
- Lo Sasso B, Giglio RV, Vidali M, et al. Evaluation of anti-SARS-Cov-2 S-RBD IgG antibodies after COVID-19 mRNA BNT162b2 vaccine. Diagnostics (Basel) 2021;11:1135.
- Favresse J, Bayart JL, Mullier F, et al. Antibody titres decline 3-month post-vaccination with BNT162b2. Emerg Microbes Infect 2021;10:1495-8. https://doi.org/10.1080/22221751.2021.1953403
- Barin B, Kasap U, Selcuk F, Volkan E, Uluckan O. Comparison of SARS-CoV-2 anti-spike receptor binding domain IgG antibody responses after CoronaVac, BNT162b2, ChAdOx1 COVID-19 vaccines, and a single booster dose: a prospective, longitudinal population-based study. Lancet Microbe 2022;3:e274-83. https://doi.org/10.1016/S2666-5247(21)00305-0
- Wanlapakorn N, Suntronwong N, Phowatthanasathian H, et al. Safety and immunogenicity of heterologous and homologous inactivated and adenoviral-vectored COVID-19 vaccine regimens in healthy adults: a prospective cohort study. Hum Vaccin Immunother 2022;18:2029111.
- Giefing-Kroll C, Berger P, Lepperdinger G, Grubeck-Loebenstein B. How sex and age affect immune responses, susceptibility to infections, and response to vaccination. Aging Cell 2015;14:309-21. https://doi.org/10.1111/acel.12326
- Wagner A, Garner-Spitzer E, Jasinska J, et al. Age-related differences in humoral and cellular immune responses after primary immunisation: indications for stratified vaccination schedules. Sci Rep 2018;8:9825.
- Ramasamy MN, Minassian AM, Ewer KJ, et al. Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. Lancet 2021;396:1979-93.
- Ewer KJ, Barrett JR, Belij-Rammerstorfer S, et al. T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial. Nat Med 2021;27:270-8. https://doi.org/10.1038/s41591-020-01194-5
- Lee SW, Moon JY, Lee SK, et al. Anti-SARS-CoV-2 spike protein RBD antibody levels after receiving a second dose of ChAdOx1 nCov-19 (AZD1222) vaccine in healthcare workers: lack of association with age, sex, obesity, and adverse reactions. Front Immunol 2021;12:779212.
- Pellini R, Venuti A, Pimpinelli F, et al. Early onset of SARS-COV-2 antibodies after first dose of BNT162b2: correlation with age, gender and BMI. Vaccines (Basel) 2021;9:685.
- Islam Z, Yamamoto S, Mizoue T, et al. Association of impaired fasting glucose and diabetes with SARS-CoV-2 spike antibody titers after the BNT162b2 vaccine among health care workers in a tertiary hospital in Japan. Vaccines (Basel) 2022;10:776.
- D'Addio F, Sabiu G, Usuelli V, et al. Immunogenicity and safety of SARS-CoV-2 mRNA vaccines in a cohort of patients with type 1 diabetes. Diabetes 2022;71:1800-6. https://doi.org/10.2337/db22-0053
- Shomali N, Mahmoudi J, Mahmoodpoor A, et al. Harmful effects of high amounts of glucose on the immune system: an updated review. Biotechnol Appl Biochem 2021;68:404-10. https://doi.org/10.1002/bab.1938
- Mayasari NR, Ho DK, Lundy DJ, et al. Impacts of the COVID-19 pandemic on food security and diet-related lifestyle behaviors: an analytical study of Google Trends-based query volumes. Nutrients 2020;12:3103.
- Ozgocer T, Dagli SN, Ceylan MR, Disli F, Ucar C, Yildiz S. Analysis of long-term antibody response in COVID-19 patients by symptoms grade, gender, age, BMI, and medication. J Med Virol 2022;94:1412-8. https://doi.org/10.1002/jmv.27452
- Grant WB, Lahore H, McDonnell SL, et al. Evidence that vitamin D supplementation could reduce risk of influenza and COVID-19 infections and deaths. Nutrients 2020;12:988.
- Murdaca G, Tonacci A, Negrini S, et al. Emerging role of vitamin D in autoimmune diseases: an update on evidence and therapeutic implications. Autoimmun Rev 2019;18:102350.
- Di Matteo G, Spano M, Grosso M, et al. Food and COVID-19: preventive/co-therapeutic strategies explored by current clinical trials and in silico studies. Foods 2020;9:1036.
- Naaber P, Tserel L, Kangro K, et al. Dynamics of antibody response to BNT162b2 vaccine after six months: a longitudinal prospective study. Lancet Reg Health Eur 2021;10:100208.
- Zhuang CL, Lin ZJ, Bi ZF, et al. Inflammation-related adverse reactions following vaccination potentially indicate a stronger immune response. Emerg Microbes Infect 2021;10:365-75. https://doi.org/10.1080/22221751.2021.1891002
- Park JW, Lagniton PN, Liu Y, Xu RH. mRNA vaccines for COVID-19: what, why and how. Int J Biol Sci 2021;17:1446-60. https://doi.org/10.7150/ijbs.59233